

Brian A Jonas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4751692/publications.pdf>

Version: 2024-02-01

97
papers

5,052
citations

257101

24
h-index

95083

68
g-index

97
all docs

97
docs citations

97
times ranked

4962
citing authors

#	ARTICLE	IF	CITATIONS
1	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	13.9	1,407
2	Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	0.6	1,254
3	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 216-228.	5.1	551
4	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 984-997.	5.1	330
5	How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2795-2804.	3.3	123
6	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. <i>American Journal of Hematology</i> , 2021, 96, 208-217.	2.0	95
7	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 855-865.	0.8	86
8	SMRT and N-CoR Corepressors Are Regulated by Distinct Kinase Signaling Pathways. <i>Journal of Biological Chemistry</i> , 2004, 279, 54676-54686.	1.6	76
9	Alternative mRNA Splicing of SMRT Creates Functional Diversity by Generating Corepressor Isoforms with Different Affinities for Different Nuclear Receptors. <i>Journal of Biological Chemistry</i> , 2005, 280, 7493-7503.	1.6	59
10	Corepressors: Custom Tailoring and Alterations While you Wait. <i>Nuclear Receptor Signaling</i> , 2005, 3, nrs.03003.	1.0	58
11	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 803-811.	2.0	51
12	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. <i>Leukemia Research</i> , 2016, 50, 123-131.	0.4	50
13	Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 791-799.	1.2	43
14	MDS prognostic scoring systems – Past, present, and future. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 3-13.	0.7	42
15	A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2943-2953.	2.0	42
16	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. <i>Cancer</i> , 2018, 124, 1938-1945.	2.0	40
17	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	0.6	39
18	Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. <i>British Journal of Haematology</i> , 2017, 178, 72-80.	1.2	38

#	ARTICLE	IF	CITATIONS
19	Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. <i>Frontiers in Oncology</i> , 2021, 11, 649209.	1.3	36
20	Response of SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor) and N-CoR (Nuclear Receptor Corepressor) Corepressors to Mitogen-Activated Protein Kinase Kinase Kinase Cascades Is Determined by Alternative mRNA Splicing. <i>Molecular Endocrinology</i> , 2007, 21, 1924-1939.	3.7	34
21	Alternative mRNA Splicing of Corepressors Generates Variants That Play Opposing Roles in Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2011, 286, 44988-44999.	1.6	31
22	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.	0.6	30
23	Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. <i>Blood</i> , 2018, 132, 285-285.	0.6	29
24	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26
25	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	0.6	23
26	Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. <i>Blood</i> , 2019, 134, 760-760.	0.6	23
27	Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. <i>Blood Cancer Journal</i> , 2017, 7, e605-e605.	2.8	22
28	New and emerging therapies for acute myeloid leukaemia. <i>Journal of Investigative Medicine</i> , 2018, 66, 1088-1095.	0.7	21
29	Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 20, 102004.	1.7	21
30	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. <i>Blood</i> , 2018, 132, 767-767.	0.6	21
31	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 78-85.	3.0	20
32	<p>Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place</p>. <i>Core Evidence</i> , 2019, Volume 14, 3-17.	4.7	20
33	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. <i>Blood</i> , 2018, 132, 331-331.	0.6	19
34	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Aynndrome (MDS): Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 1452-1452.	0.6	16
35	Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax Combined with Hypomethylating Agents. <i>Blood</i> , 2021, 138, 224-224.	0.6	16
36	Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: A novel variant of myeloid proliferative neoplasm with eosinophilia. <i>Human Pathology: Case Reports</i> , 2016, 5, 6-9.	0.2	15

#	ARTICLE	IF	CITATIONS
37	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 509-515.e1.	0.2	15
38	Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	14
39	Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 423-436.	1.0	14
40	Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. <i>Future Oncology</i> , 2021, 17, 2989-3005.	1.1	13
41	Optimal Molecular Methods in Detecting p190^{BCR-ABL} Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2015, 2015, 1-6.	0.3	12
42	Paraneoplastic leukemoid reaction as a marker of tumor progression in non-small cell lung cancer. <i>Cancer Treatment Communications</i> , 2015, 4, 15-18.	0.4	12
43	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	2.8	12
44	Complications and early mortality in patients with acute promyelocytic leukemia treated in California. <i>American Journal of Hematology</i> , 2018, 93, E370-E372.	2.0	11
45	A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E291-E294.	2.0	11
46	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 5.	2.8	11
47	Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study. <i>Blood</i> , 2020, 136, 51-53.	0.6	10
48	Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	8
49	Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. <i>Nanomedicine</i> , 2014, 9, 1807-1820.	1.7	7
50	Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. <i>Toxics</i> , 2019, 7, 27.	1.6	7
51	Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-“PD-L1) Tj ETQq1 1 0.784314 rgBT /Over acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2711-2714.	0.6	6
52	Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. <i>Case Reports in Hematology</i> , 2017, 2017, 1-5.	0.3	5
53	Phase <scp>k</scp> study of escalating doses of carfilzomib with <scp>HyperCVAD</scp> in patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E114-E117.	2.0	5
54	On the origin of relapse in AML. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	5

#	ARTICLE	IF	CITATIONS
55	Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3897-3897.	0.6	5
56	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. <i>Blood</i> , 2016, 128, 4049-4049.	0.6	5
57	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
58	Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. <i>Chemical Research in Toxicology</i> , 2018, 31, 1042-1051.	1.7	4
59	Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. <i>Blood</i> , 2018, 132, 1424-1424.	0.6	4
60	CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study. <i>Blood</i> , 2020, 136, 50-52.	0.6	4
61	B lymphoblastic leukemia with granules mimicking acute myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 102, 251-252.	0.7	3
62	First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S203.	0.2	3
63	Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 846-846.	0.6	3
64	Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis. <i>Cancers</i> , 2015, 7, 2459-2465.	1.7	2
65	Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. <i>Case Reports in Hematology</i> , 2015, 2015, 1-5.	0.3	2
66	Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. <i>PLoS ONE</i> , 2016, 11, e0159189.	1.1	2
67	Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results. <i>Annals of Oncology</i> , 2019, 30, vi81.	0.6	2
68	Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S221-S222.	0.2	2
69	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 453-458.	0.2	2
70	From MDS/AML to iPSC and back again. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	2
71	Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 539-539.	0.6	2
72	Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study. <i>Blood</i> , 2016, 128, 3982-3982.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Reports in Hematology, 2020, 2020, 1-6.	0.3	2
74	HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study. Blood, 2020, 136, 1-1.	0.6	2
75	Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leukemia Research, 2022, 119, 106885.	0.4	2
76	Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961876420.	0.3	1
77	Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S201.	0.2	1
78	Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clinical Cancer Research, 2021, 27, 4726-4736.	3.2	1
79	Novel drug combination unleashes apoptosis in AML. Science Translational Medicine, 2018, 10, .	5.8	1
80	A new therapeutic target for myelofibrosis is cause for Gli. Science Translational Medicine, 2017, 9, .	5.8	1
81	A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood, 2018, 132, 4018-4018.	0.6	1
82	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35.	0.6	1
83	DIFFERENTIAL REGULATION OF NUCLEAR COREPRESSOR PROTEINS, SILENCING MEDIATOR OF RETIONIC ACID AND THYROID HORMONE RECEPTORS AND NUCLEAR HORMONE RECEPTOR COREPRESSOR.. Journal of Investigative Medicine, 2004, 52, S146.	0.7	0
84	KINASE SIGNALING AND ALTERNATIVE MESSENGER RIBONUCLEIC ACID SPLICING: TWO METHODS TO CUSTOMIZE SMRT AND N-COR FUNCTION WITHIN THE CELL.. Journal of Investigative Medicine, 2007, 55, S140.	0.7	0
85	An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Review of Hematology, 2021, 14, 407-417.	1.0	0
86	Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e611-e618.	0.2	0
87	Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leukemia and Lymphoma, 2022, 63, 231-234.	0.6	0
88	Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact. Blood, 2015, 126, 1305-1305.	0.6	0
89	The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment. Blood, 2015, 126, 1991-1991.	0.6	0
90	Abstract 1313: Targeting micelles eradicate acute myeloid leukemia stem cells in a patient-derived leukemia xenograft model. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
91	Efficacy and Tolerability of Hyper-CVAD in Adult Acute Lymphoblastic Patients: A Retrospective Analysis at a Comprehensive Cancer Center. <i>Blood</i> , 2016, 128, 5195-5195.	0.6	0
92	Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California. <i>Blood</i> , 2016, 128, 391-391.	0.6	0
93	“CHIPs” are bad for patients with solid tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	0
94	Just say NO to leaky bone marrow vasculature in AML. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	0
95	Vascular endothelial cells take hematopoietic stem cells to school. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	0
96	Assessing the Quality of Electronic Data for 'Fit-for-Purpose' by Utilizing Data Profiling Techniques Prior to Conducting a Survival Analysis for Adults with Acute Lymphoblastic Leukemia. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 915-924.	0.2	0
97	Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center. <i>Blood</i> , 2020, 136, 28-28.	0.6	0